Study study type
PathologyT1T0Patientssample sizesROB Results deaths (OS) Eprogression or deaths (PFS) ERFS/DFS E

breast cancer - adjuvant breast cancer - adjuvant

versus trastuzumab
trastuzumab emtansine
KATHERINE, 2019
  NCT01772472		RCTes-BC - HER2 positive - (neo)adjuvant (NA)trastuzumab emtasine (T-DM1)trastuzumabPatients had histologically confirmed, HER2-positive, nonmetastatic, invasive primary breast cancer and if residual invasive disease after completion of taxane-based neoadjuvant chemotherapy ad and had to have completed at least six cycles (16 weeks) of a conventional preoperative chemotherapy regimen containing a minimum of 9 weeks of taxane-based therapy and 9 weeks of trastuzumab therapy.743 / 743high
 conclusif -30%

es-BC - HER2 positive - (neo)adjuvant (NA) breast cancer - HER2-positive es-BC - HER2 positive - (neo)adjuvant (NA)

versus trastuzumab
trastuzumab emtansine
KATHERINE, 2019
  NCT01772472		RCTes-BC - HER2 positive - (neo)adjuvant (NA)trastuzumab emtasine (T-DM1)trastuzumabPatients had histologically confirmed, HER2-positive, nonmetastatic, invasive primary breast cancer and if residual invasive disease after completion of taxane-based neoadjuvant chemotherapy ad and had to have completed at least six cycles (16 weeks) of a conventional preoperative chemotherapy regimen containing a minimum of 9 weeks of taxane-based therapy and 9 weeks of trastuzumab therapy.743 / 743high
 conclusif -30%
versus trastuzumab plus endocrine therapy
trastuzumab emtansine
Harbeck (TDM-1), 2017 RCTes-BC - HER2 positive - (neo)adjuvant (NA), es-BC - HR positive - (neo)adjuvant (NA)trastuzumab emtasinetrastuzumab plus endocrine therapyWomen older than 18yr with histologically confirmed unilateral primary BC, no evidence of distant metastasis, ER and/or PR-positive and HER2-positive who were candidates for neoadjuvant chemotherapy were eligible119 / 129NA
 suggested
trastuzumab emtasine plus endocrine therapy
Harbeck (TDM1 plus ET), 2017
  NCT01817452		RCTes-BC - HER2 positive - (neo)adjuvant (NA), es-BC - HR positive - (neo)adjuvant (NA)trastuzumab emtasine plus endocrine therapytrastuzumab plus endocrine therapyWomen older than 18yr with histologically confirmed unilateral primary BC, no evidence of distant metastasis, ER and/or PR-positive and HER2-positive who were candidates for neoadjuvant chemotherapy were eligible-/-NA
 suggested

la/mBC - HER2 positive - 2nd Line (L2) breast cancer - HER2-positive la/mBC - HER2 positive la/mBC - HER2 positive - 2nd Line (L2)

versus lapatinib plus capecitabine
trastuzumab emtansine
EMILIA, 2012
  NCT00829166		RCTla/mBC - HER2 positive - 2nd Line (L2)trastuzumab emtansinelapatinib plus capecitabinepatients with HER2-positive unresectable, locally advanced or metastatic breast cancer, who had previously been treated with trastuzumab and a taxane.495 / 496some concern
 conclusif demonstrated-32% demonstrated-35%
versus trastuzumab emtansine
trastuzumab deruxtecan
DESTINY Breast03, 2022
  NCT03529110		RCTla/mBC - HER2 positive - 2nd Line (L2)trastuzumab deruxtecantrastuzumab emtansinepatients with HER2-positive metastatic breast cancer previously treated with trastuzumab and a taxane-/-some concern
 suggested -45% -72%

es-BC - HR positive - (neo)adjuvant (NA) breast cancer - HR positive es-BC - HR positive - (neo)adjuvant (NA)

versus trastuzumab plus endocrine therapy
trastuzumab emtansine
Harbeck (TDM-1), 2017 RCTes-BC - HER2 positive - (neo)adjuvant (NA), es-BC - HR positive - (neo)adjuvant (NA)trastuzumab emtasinetrastuzumab plus endocrine therapyWomen older than 18yr with histologically confirmed unilateral primary BC, no evidence of distant metastasis, ER and/or PR-positive and HER2-positive who were candidates for neoadjuvant chemotherapy were eligible119 / 129NA
 suggested
trastuzumab emtasine plus endocrine therapy
Harbeck (TDM1 plus ET), 2017
  NCT01817452		RCTes-BC - HER2 positive - (neo)adjuvant (NA), es-BC - HR positive - (neo)adjuvant (NA)trastuzumab emtasine plus endocrine therapytrastuzumab plus endocrine therapyWomen older than 18yr with histologically confirmed unilateral primary BC, no evidence of distant metastasis, ER and/or PR-positive and HER2-positive who were candidates for neoadjuvant chemotherapy were eligible-/-NA
 suggested

mBC-Triple negative (TNBC) - 2nd Line (L2) breast cancer - triple negative mBC-Triple negative (TNBC) - 2nd Line (L2)

versus Standard of Care (SoC)
sacituzumab govitecan
ASCENT (all population), 2021
  NCT02574455		RCTmBC-Triple negative (TNBC) - 2nd Line (L2)Sacituzumab govitecansingle agent chemotheraopy of the physician's choice (eribulin, vinorelbine, capecitabine or gemcitabine)Patients with metastatic triple-negative breast cancer that was relapsed or refractory to two or more previous standard chemotherapy regimens for unresectable, locally andvanced or metastatic disease (previous thearapy had to include taxanes).267 / 262NA
 suggested -49% -57%
ASCENT (patients without brain metastases), 2021
  NCT02574455		RCTmBC-Triple negative (TNBC) - 2nd Line (L2)Sacituzumab govitecansingle agent chemotheraopy² of the physician's choice (eribulin, vinorelbine, capecitabine or gemcitabine)Patients with metastatic triple-negative breast cancer that was relapsed or refractory to two or more previous standard chemotherapy regimens for unresectable, locally andvanced or metastatic disease (previous thearapy had to include taxanes).235 / 233NA
 suggested -52% -59%

metastatic/advanced - breast cancer (mBC) metastatic/advanced - breast cancer (mBC)

versus chemotherapy
trastuzumab deruxtecan
DESTINY-Breast04, 2022
  NCT03734029		RCTmetastatic/advanced - breast cancer (mBC)trastuzumab deruxtecanphysician’s choice of chemotherapypatients with HER2-low metastatic breast cancer who had received one or two previous lines of chemotherapy373 / 184some concern
 conclusif demonstrated-36% demonstrated-50%

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons